Introduction {#s1}
============

*Botrytis cinerea* is a necrotrophic fungal pathogen that causes gray mold, a seriously destructive postharvest disease that affects a variety of fresh fruits (Saito et al., [@B32]). Even at low temperature during storage and transportation, it can produce significant degradation in fruit quality, resulting in severe economic losses. Because chemical fungicides are harmful to human health and the environment, there is an urgent need to develop safe and effective antifungal agents to control the decay caused by *B. cinerea*. Natural antimicrobial agents such as essential oils provide one promising alternative. For example, the essential oils of *Origanum compactum* and *Thymus glandulosus* strongly inhibit the growth of mycelia in *B. cinerea* (Bouchra et al., [@B7]), and essential oils from three *Monarda* species have antifungal effects on both mycelia and spores (Adebayo et al., [@B1]). *Syzygium aromaticum, Brassica nigra*, and *Solidago canadensis* L. essential oils also exhibit effective antifungal activity in strawberries against *B. cinerea in vitro* and *in vivo* (Aguilar-González et al., [@B2]; Liu et al., [@B24]).

Tea tree oil (TTO), the volatile essential oil extracted from leaves and branches of the Australian native plant *Melaleuca alternifolia* by steam distillation, is frequently used as a topical medicinal and antimicrobial agent (Pazyar et al., [@B28]). Because of its bioactivities, its efficacy has recently been evaluated against *Staphylococcus aureus, Escherichia coli, Aspergillus niger*, and *Candida albicans in vitro* (Gustafson et al., [@B13]; Hammer et al., [@B14]; Shi et al., [@B36]). TTO controls the growth of *B. cinerea* more effectively than pine and cinnamon oil (Szczerbanik et al., [@B39]), or clove oil and garlic oil (Cheng and Shao, [@B9]). TTO also effectively inhibits the growth of *B. cinerea* on Dutch White cabbage (Bishop and Reagan, [@B4]) and exhibits high antifungal activity on *B. cinerea* in strawberry fruit (Shao et al., [@B35]).

Essential oils are generally thought to exert their antifungal activity by damaging plasma membranes (Hood et al., [@B16]; Khan et al., [@B17]) and mitochondria (Tian et al., [@B41]; Zheng et al., [@B45]; Li et al., [@B19]). Microscopic observations revealed that the essential oils of *Origanum syriacum* L. var. *bevanii* and *Lavandula stoechas* L. var. *stoechas* caused considerable morphological degenerations of the fungal hyphae of *B. cinerea* such as cytoplasmic coagulation, vacuolations, hyphal shriveling and protoplast leakage, and loss of conidiation (Soylu et al., [@B38]). Our previous studies confirmed that TTO primarily targets the *B. cinerea* cell wall, resulting in increased membrane permeability, the release of cellular material, and eventual cell death (Shao et al., [@B34]). Terpinen-4-ol, the major characteristic component of TTO, severely compromises membrane integrity and increases permeability. Another characteristic component in TTO, 1,8-cineole, damages cellular organelles but does not affect membrane permeability (Yu et al., [@B44]). These findings are important clues for understanding TTO antifungal activity, although the underlying mechanisms are still not fully clear.

Metabolomics is an emerging technology that provides a comprehensive quantitative and qualitative inventory of the low molecular weight metabolites in a cell or organism (Fiehn et al., [@B10]). It is particularly useful for analyzing changes in the endogenous metabolism of a biological system that has been stimulated or disturbed, and for identifying metabolic pathways. Recently, metabolomics has been widely applied to study the mechanisms by which different agents exert their antimicrobial effects against fungi and bacteria. For example, the activity of amphotericin B against *C. albicans* can be attributed to changes in metabolite production (Cao et al., [@B8]). Another study found that the microbiostatic effect of ε-Poly-L-lysine on *Saccharomyces cerevisiae* is achieved by breaking the balance of intracellular metabolites due to disruptions in cell membrane function (Bo et al., [@B5]). Finally, a metabolomics approach was used to demonstrate that cinnamaldehyde changes the metabolism of *E. coli* by interacting with different biochemical targets (Mousavi et al., [@B26]).

No studies have yet employed metabolomics to examine changes in fungi in the presence of essential oils. In order to examine the antifungal effects of TTO on *B. cinerea* in detail, we conducted a metabolomics analysis using an ultra-high pressure liquid chromatography system coupled to a quadrupole time-of-flight mass spectrometer (UHPLC-Q-TOF MS).

This study was designed to reveal the mechanisms responsible for the antifungal effects and stress caused by TTO in *B. cinerea* by generating a high-resolution metabolic fingerprint and detecting changes in metabolite levels at high sensitivity.

Materials and methods {#s2}
=====================

Fungal isolates, essential oil, and reagents
--------------------------------------------

A highly virulent strain of *B. cinerea* was isolated from strawberries and cultured at 25°C on potato dextrose agar medium (PDA; containing 1 L of an infusion from potatoes, 20 g/L glucose, and 15 g/L agar) before use in experiments. TTO was purchased from Fuzhou Merlot Lotus Biological Technology Company (Fujian Province, China). Ammonium acetate and ammonium hydroxide were purchased from Sigma Aldrich (St. Louis, MO, USA). Acetonitrile and methanol were purchased from Merck (Germany). Ammonium acetate and acetonitrile were of HPLC-grade. Distilled water was filtered through a Milli-Q system from EMD Millipore Corporation (Billerica, MA, USA). Succinate dehydrogenase (SDH), malic dehydrogenase (MDH), citrate synthase (CS), isocitrate dehydrogenase (ICDH), α-ketoglutarate dehydrogenase (α-KGDH), and hydrogen peroxide (H~2~O~2~) reagent kits were purchased from Nanjing Jian Cheng Bioengineering Institute (Nanjing, China).

Fungal culture and sample preparation
-------------------------------------

*B. cinerea* cultures were maintained on PDA at 25°C for 3 days. The spore suspension was harvested by adding 10 mL sterile 0.9% NaCl solution to each petri dish and gently scraping the mycelial surface three times with a sterile L-shaped spreader to free the spores. The spore suspension was adjusted using a hemocytometer to 5 × 10^6^ spores/mL. One milliliter suspension was inoculated into 250 mL flasks containing 150 mL sterile potato dextrose broth (PDB; containing 1 L of an infusion from potatoes, 20 g/L glucose) medium and cultured at 25°C on a rotary shaker at 150 revolutions per minute (rpm) for 3 days. TTO was added to the medium to a final concentration of 5 mL/L, and cultures incubated for 2 h. Mycelia were then collected, rinsed three times with 0.1 M phosphate buffer saline (PBS; pH = 7.4), and immediately frozen in liquid nitrogen. Samples were stored at −80°C. Cultures without TTO were used as a control. Six samples of each group were prepared in parallel for LC-MS/MS analysis and other tests.

LC--MS/MS analysis
------------------

Before analysis, control and treated mycelia (\~100 mg wet weight) were thawed at 4°C and homogenized. One milliliter of acetonitrile and methanol (1:1, v/v) was added to each sample and mixed by vortexing. Samples were immediately frozen in liquid nitrogen, subjected to ultrasonic grinding for 10 min, stirred for 60 min at −20°C, and then separated by centrifugation at 12,000 × g for 15 min at 4°C. An aliquot of 900 μL supernatant was dried under vacuum, dissolved in 100 μL of acetonitrile and water (1:1, v/v) by vortexing, and centrifuged at 12,000 × g for 15 min at 4°C. The chemical compositions of the samples were analyzed using an UHPLC (1290 Infinity LC, Agilent Technologies) equipped with a quadrupole time-of-flight (AB Sciex TripleTOF 6600) mass spectrometer.

For separation by hydrophilic interaction liquid chromatography (HILIC), samples were analyzed using a 2.1 mm × 100 mm ACQUIY UPLC BEH 1.7 μm column (Waters Corporation, Ireland). In both electron spray ionization (ESI) positive and negative modes, the mobile phase contained (A) 25 mM ammonium acetate and 25 mM ammonium hydroxide in water, and (B) acetonitrile. The elution gradient was: 0--1 min, 85% B; 1--12 min, 85--65% B; 12--12.1 min, 65--40% B; 12.1--15 min, 40% B; 15--15.1 min, 40--85% B; 15.1--20 min, 85% B, with a 5 min re-equilibration period employed.

The ESI source conditions were set as follows: Ion Source Gas1 (Gas1) as 60, Ion Source Gas2 (Gas2) as 60, curtain gas (CUR) as 30, source temperature: 600°C, Ion Spray Voltage Floating (ISVF) ±5,500 V. In the MS only acquisition mode, the instrument was set to acquire over the m/z range 60--1,000 Da, and the accumulation time for the TOF MS scan was set at 0.20 s/spectrum. In the auto MS/MS acquisition mode, the instrument was set to acquire over the m/z range 25--1,000 Da, and the accumulation time for product ion scan was set at 0.05 s/spectrum. The product ion scan was acquired using information dependent acquisition (IDA) with the high sensitivity mode selected. The collision energy (CE) was fixed at 35 V ± 15 eV. The declustering potential (DP) was set to ±60 V.

Determination of effect of TTO on the leakage of cell membrane
--------------------------------------------------------------

In order to assess TTO affect on the leakage of cell membrane, the absorbance at 260 nm of *B. cinerea* cell was determined. As described above for fungal culture and sample preparation, TTO was added to PDB medium at a final concentration of 5 mL/L. PDB without TTO served as the control. Treated and control group were centrifuged at 10,000 × *g* for 10 min at 4°C, and the absorbance of the supernatant was measured immediately at 260 nm with a UV/Vis spectrophotometer (UV-2000, UNICO Instrument Co., Ltd., Shanghai, China). After 2 h incubation with or without TTO, treated and control group were centrifuged and the absorbance at 260 nm of the obtained supernatant were measured. Each treatment was performed in triplicates. The percentage change in A~260nm~ (Liu et al., [@B22]) was calculated using the following formula: $$\text{A}_{260\text{\,nm}}\text{~percentage~change}(\%) = \lbrack(\text{A}_{\text{t}} - \text{A}_{0})/\text{A}_{0}\rbrack \times 100$$ where A~0~ is the mean A~260nm~ for cultures measured after 0 h of treatment, and A~t~ is the mean A~260nm~ for cultures after 2 h of treatment.

Activities of key enzymes involved in tricarboxylic acid (TCA) cycle
--------------------------------------------------------------------

Control and treated mycelia were washed with 0.1M PBS (pH = 7.4) three times and then ground in liquid nitrogen. The ground material was suspended in 10 mL 0.05M PBS (pH = 7.2) and centrifuged at 10,000 × *g* for 10 min at 4°C. Enzyme activities were measured in the supernatant for SDH, MDH, CS, ICDH, and α-KGDH, using commercially available kits purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China) following the manufacturer\'s instructions. ICDH, MDH, and α-KGDH activities were detected at 340 nm in redox reaction assays. SDH and CS activities were determined at 600 and 412 nm, respectively. All tests were performed in triplicate.

Determination of effect of TTO on H~2~O~2~ accumulation
-------------------------------------------------------

Control and treated mycelia (1 g wet weight) were mixed with 5 mL 0.05 M PBS (pH = 7.0, containing 3% polyvinyl pyrrolidone), subjected to ultrasonic grinding for 15 min, and centrifuged at 10,000 × *g* for 10 min at 4°C. The supernatant was used to determine H~2~O~2~ content of the fungal cells using assay kits obtained from Nanjing Jiancheng Institute of Bioengineering (Nanjing, Jiangsu, China) following the manufacturer\'s instructions. H~2~O~2~ content was expressed as mmol/g prot. All tests were performed in triplicate.

Data processing
---------------

The raw MS data (.wiff scan files) were converted to MzXML format using ProteoWizard MSConvert and processed using XCMS for feature detection, retention time correction, and alignment. Metabolites were identified by matching high accuracy (\<25 ppm) MS/MS data to our standards database.

Statistical analysis
--------------------

In the extracted ion features, only variables having more than 50% of the non-zero measurement values in at least one group were retained. For multivariate statistical analysis, the Metabo Analyst (<http://www.metaboanalyst.ca>) web-based system was used. After Pareto scaling, principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA) were performed. Leave-one-out cross-validation and response permutation testing were used to evaluate the robustness of the model. Metabolites exhibiting significant differences were identified based on the combination of a statistically significant threshold of variable influence on projection (VIP) values obtained from a PLS-DA model and a two-tailed Student\'s *t*-test (*p*-value) on the raw data. Metabolites with VIP-values larger than 1.0 and *p* \< 0.05 were considered significant. All enzyme activity and H~2~O~2~ content data were analyzed using SAS software (Version 8.2; SAS Institute, Cary, NC, USA). These data were analyzed by one-way analysis of variance (ANOVA). Comparison of means was performed by Duncan\'s multiple range tests. A value of *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Multivariate analysis
---------------------

Extracts from TTO-treated and untreated *B. cinerea* were analyzed using a UHPLC-Q-TOF mass spectrometer in positive and negative ion modes. Multivariate analysis was applied to find potential biomarkers. PCA, an unsupervised pattern recognition method, was performed to examine intrinsic variation in the data set. Samples that have similar metabolomics profiles are clustered together and those that are different are placed further apart in PCA score plots. As shown by the PCA score plots in positive (Figure [1A](#F1){ref-type="fig"}) and negative (Figure [1B](#F1){ref-type="fig"}) ion modes, the control group and TTO-treated group clustered separately, which indicates that metabolite levels were altered in the TTO-treated group.

![Score plots representing PCA and PLS-DA results based on the UHPLC-Q-TOF MS spectra *B. cinerea* mycelia from the TTO-treated cells (green dots) and control cells (red dots) are shown in **(A,C)** positive and **(B,D)** negative modes. C, control sample; T, TTO-treated sample.](fmicb-08-01017-g0001){#F1}

To further identify ion peaks that could discriminate between the groups, a supervised pattern recognition method (PLS-DA) was suitable for the selection of biomarkers in similar metabolic profiling data (Schneider et al., [@B33]). In the PLS-DA score plots for both the positive (Figure [1C](#F1){ref-type="fig"}) and negative (Figure [1D](#F1){ref-type="fig"}) ion modes, metabolic differences made it possible to resolve the control and TTO-treated groups into distinct clusters. The *R*^2^ and *Q*^2^ parameters are used to evaluate the quality of the PLS-DA model. The *R*^2^ and *Q*^2^ were 0.99 and 0.97 in positive ion mode, respectively, and *R*^2^ and *Q*^2^ were 0.99 and 0.96 in negative ion mode, indicating that the model had high predictability and reliability.

Selection and identification of biomarkers
------------------------------------------

To find the endogenous metabolites that contributed most to the separation of the control and TTO-treated samples, VIP scores were determined after PLS-DA. VIP measures the contribution made by each variable to the PLS-DA model. Ions were considered as potential biomarkers if they satisfied the criteria VIP-value \> 1 and *p*-value \< 0.05. Based on this algorithm, 91 metabolite ions were identified as primary contributors to the separation between control and TTO-treated groups. The data are summarized in Table [1](#T1){ref-type="table"}, which also classifies the metabolites as either upregulated (8 metabolites) or downregulated (83 metabolites).

###### 

Identification and changes in levels of potential biomarkers in *B. cinerea* cells.

  **Metabolite**                       **Ionization mode**   **RT (min)**   **VIP**   **Fold change**   ***P*-value**    **m/z**     **Trend (treated vs. control)**   **Functional category**
  ------------------------------------ --------------------- -------------- --------- ----------------- ---------------- ----------- --------------------------------- ---------------------------------
  Trehalose                            ESI(−)                8.68           1.75      0.08              8.53 × 10^−7^    401.12816   ↓                                 Oxidative stress
  Succinate                            ESI(−)                8.21           1.91      0.05              8.17 × 10^−8^    117.02004   ↓                                 TCA cycle
  Myristic acid                        ESI(−)                1.18           1.87      0.06              3.89 × 10^−5^    287.22120   ↓                                 Lipid metabolism
  L-Malic acid                         ESI(−)                11.17          1.41      0.17              2.02 × 10^−5^    133.01430   ↓                                 TCA cycle
  L-Glutamate                          ESI(+), ESI(−)        8.51           1.52      0.13              1.41 × 10^−7^    146.04635   ↓                                 Amino acid metabolism
  L-Alanine                            ESI(−)                6.60           1.45      0.15              6.07 × 10^−5^    88.04234    ↓                                 Amino acid metabolism
  Isocitrate                           ESI(−)                11.22          1.24      0.20              2.12 × 10^−3^    191.01933   ↓                                 TCA cycle
  Hypoxanthine                         ESI(+), ESI(−)        2.37           1.20      0.24              3.44 × 10^−4^    135.03135   ↓                                 Purine metabolism
  Xanthine                             ESI(+)                3.44           1.13      0.32              1.10 × 10^−4^    153.03962   ↓                                 Purine metabolism
  PC(16:0/16:0)                        ESI(+)                1.00           1.13      0.32              7.10 × 10^−5^    778.53738   ↓                                 Lipid metabolism
  L-Proline                            ESI(+)                1.73           1.94      0.05              2.21 × 10^−3^    157.09589   ↓                                 Amino acid metabolism
  L-Phenylalanine                      ESI(+)                5.50           2.13      0.04              4.55 × 10^−8^    165.07486   ↓                                 Amino acid metabolism
  L-Histidine                          ESI(+)                13.58          1.40      0.17              1.42 × 10^−3^    156.07622   ↓                                 Amino acid metabolism
  L-Glutamine                          ESI(+)                8.15           1.01      0.38              3.42 × 10^−4^    147.07577   ↓                                 Amino acid metabolism
  L-Citrulline                         ESI(+)                7.54           1.82      0.08              6.17 × 10^−4^    217.12910   ↓                                 Amino acid metabolism
  L-Carnosine                          ESI(+)                6.52           1.88      8.54              4.06 × 10^−5^    227.11334   ↑                                 Amino acid metabolism
  L-Arginine                           ESI(+)                14.07          1.06      0.26              0.05             175.11853   ↓                                 Amino acid metabolism
  Imidazoleacetic acid                 ESI(+)                7.40           1.47      3.44              1.61 × 10^−6^    270.11914   ↑                                 Amino acid metabolism
  GMP^172^                             ESI(+)                10.42          1.04      0.37              1.09 × 10^−5^    364.06465   ↓                                 Purine metabolism
  Guanosine                            ESI(+), ESI(−)        4.04           1.17      2.27              0.04             282.08322   ↑                                 Purine metabolism
  D-Mannitol                           ESI(+)                5.49           2.00      0.06              2.54 × 10^−8^    183.08529   ↓                                 Fructose and mannose metabolism
  D-Glucose 6-phosphate                ESI(+), ESI(−)        11.68          1.55      0.16              1.50 × 10^−6^    278.06307   ↓                                 Glycolysis/gluconeogenesis
  D-Glucose                            ESI(+)                11.68          1.57      0.15              4.24 × 10^−5^    243.02608   ↓                                 Glycolysis/gluconeogenesis
  Beta-D-Fructose 6-phosphate          ESI(+)                10.94          1.50      0.18              1.54 × 10^−5^    243.02559   ↓                                 Fructose and mannose metabolism
  Argininosuccinic acid                ESI(+), ESI(−)        11.46          1.38      0.19              1.63 × 10^−3^    289.11420   ↓                                 Amino acid metabolism
  alpha-Linolenic acid                 ESI(+)                1.06           1.50      0.17              1.43 × 10^−4^    279.23093   ↓                                 Lipid metabolism
  AMP                                  ESI(+), ESI(−)        10.11          1.34      0.14              4.84 × 10^−3^    346.05357   ↓                                 Purine metabolism
  Deoxyadenosine                       ESI(+)                1.97           1.06      2.29              0.06             252.10843   ↑                                 Purine metabolism
  Urocanic acid                        ESI(+)                9.76           1.21      0.26              1.59 × 10^−3^    156.07635   ↓                                 Amino acid metabolism
  UMP                                  ESI(+), ESI(−)        10.45          1.57      0.15              6.45 × 10^−5^    325.04258   ↓                                 Pyrimidine metabolism
  UDP                                  ESI(+)                10.44          1.96      0.07              1.75 × 10^−7^    405.00844   ↓                                 Pyrimidine metabolism
  UDP-N-acetylglucosamine              ESI(+), ESI(−)        10.00          2.18      0.04              2.07 × 10^−8^    608.08737   ↓                                 Peptidoglycan biosynthesis
  UDP-D-Glucose                        ESI(−)                10.42          1.90      0.06              4.60 × 10^−5^    565.04443   ↓                                 Galactose metabolism
  UDP-D-Galactose                      ESI(+)                10.44          2.00      0.06              2.03 × 10^−7^    584.08782   ↓                                 Galactose metabolism
  Thiamine                             ESI(+)                8.07           1.20      0.28              4.73 × 10^−4^    265.11128   ↓                                 Vitamin metabolism
  S-Methyl-5\'-thioadenosine           ESI(+), ESI(−)        1.28           1.74      0.07              1.34 × 10^−6^    296.08064   ↓                                 Purine metabolism
  Sebacic acid                         ESI(−)                5.92           1.59      0.10              3.22 × 10^−3^    201.11226   ↓                                 Lipid metabolism
  GMP^173^                             ESI(+)                10.42          1.04      0.37              1.09 × 10^−5^    364.06465   ↓                                 Purine metabolism
  Sarcosine                            ESI(+)                6.64           1.23      0.28              2.73 × 10^−5^    90.05550    ↓                                 Amino acid metabolism
  sn-Glycerol 3-phosphoethanolamine    ESI(−)                8.45           1.73      0.08              1.99 × 10^−5^    214.04807   ↓                                 Lipid metabolism
  Pantothenate                         ESI(+)                3.96           2.21      0.03              9.13 × 10^−6^    220.11742   ↓                                 Vitamin metabolism
  Nicotinate                           ESI(+), ESI(−)        2.79           2.27      0.03              5.47 × 10^−8^    124.03858   ↓                                 Vitamin metabolism
  ADMA                                 ESI(+)                13.49          1.21      0.29              0.02             203.14994   ↓                                 Amino acid metabolism
  Phenyllactic acid                    ESI(−)                1.40           2.07      0.03              2.98 × 10^−4^    165.05476   ↓                                 Others
  N-Acetylputrescine                   ESI(+)                6.97           1.05      0.21              0.03             131.11737   ↓                                 Others
  N-Acetyl-D-Glucosamine 6-Phosphate   ESI(+)                10.80          1.64      0.14              3.75 × 10^−6^    302.06304   ↓                                 Others
  N-Acetyl-D-glucosamine               ESI(+)                4.25           1.48      0.17              7.86 × 10^−5^    222.09609   ↓                                 Others
  N6,N6,N6-Trimethyl-L-lysine          ESI(+)                14.00          1.81      0.13              4.84 × 10^−5^    189.15917   ↓                                 Amino acid metabolism
  N,N′-Diacetylchitobiose              ESI(+)                6.80           1.84      0.09              2.35 × 10^−8^    425.17553   ↓                                 Others
  N-(omega)-Hydroxyarginine            ESI(+)                10.22          1.13      2.21              2.11 × 10^−3^    232.13999   ↑                                 Amino acid metabolism
  Maltotriose                          ESI(+)                11.43          1.71      0.12              6.16 × 10^−6^    522.20183   ↓                                 Others
  L-Saccharopine                       ESI(+), ESI(−)        10.75          1.80      0.10              3.11 × 10^−5^    277.13906   ↓                                 Amino acid metabolism
  O-Phosphotyrosine                    ESI(−)                10.44          1.54      0.12              5.58 × 10^−5^    261.03667   ↓                                 Others
  Pipecolic acid                       ESI(+)                5.37           1.53      0.13              0.01             130.08548   ↓                                 Others
  L-Methionine                         ESI(+)                4.42           1.22      2.16              6.75 × 10^−6^    150.05752   ↑                                 Amino acid metabolism
  N-Acetylmannosamine                  ESI(−)                4.75           1.43      0.12              5.70 × 10^−3^    220.08164   ↓                                 Others
  N-Acetylglucosamine 1-phosphate      ESI(−)                10.43          1.50      0.13              2.91 × 10^−4^    300.04740   ↓                                 Others
  Mesaconic acid                       ESI(−)                10.27          1.09      0.28              1.63 × 10^−5^    129.01997   ↓                                 Others
  L-Pyroglutamic acid                  ESI(+), ESI(−)        8.18           1.81      0.08              4.89 × 10^−5^    188.05548   ↓                                 Amino acid metabolism
  Homocitrate                          ESI(−)                10.94          1.73      0.11              5.10 × 10^−5^    205.03501   ↓                                 Amino acid metabolism
  Levulinic acid                       ESI(+)                8.79           1.84      0.09              6.42 × 10^−6^    134.08050   ↓                                 Others
  Isovalerylglycine                    ESI(+)                9.47           1.62      0.14              4.42 × 10^−6^    177.12276   ↓                                 Others
  Isomaltose                           ESI(+)                8.73           1.86      0.09              3.98 × 10^−8^    360.14947   ↓                                 Starch and sucrose metabolism
  Glycylproline                        ESI(+)                9.37           2.02      0.06              1.89 × 10^−7^    233.11260   ↓                                 Amino acid metabolism
  Glycyl-L-leucine                     ESI(+), ESI(−)        4.16           2.30      29.32             4.42 × 10^−4^    189.12269   ↑                                 Amino acid metabolism
  Glycerophosphocholine                ESI(+)                8.28           1.70      0.12              3.03 × 10^−10^   258.11003   ↓                                 Lipid metabolism
  Glutathione disulfide                ESI(+), ESI(−)        13.03          1.07      0.29              5.57 × 10^−3^    613.15817   ↓                                 Glutathione metabolism
  Glycerol 3-phosphate                 ESI(+), ESI(−)        10.12          1.53      0.13              2.13 × 10^−5^    171.00594   ↓                                 Lipid metabolism
  L-Gamma-Glutamylcysteine             ESI(+)                9.39           1.65      0.12              1.61 × 10^−4^    292.10237   ↓                                 Glutathione metabolism
  D-Mannose-6-phosphate                ESI(+)                11.34          1.54      0.16              3.10 × 10^−6^    243.02578   ↓                                 Fructose and mannose metabolism
  D-Biotin                             ESI(+)                3.92           1.39      0.22              3.70 × 10^−7^    245.09493   ↓                                 Vitamin metabolism
  D-Alanyl-D-alanine                   ESI(+)                6.31           1.99      0.06              1.19 × 10^−5^    143.08073   ↓                                 Amino acid metabolism
  CMP                                  ESI(+), ESI(−)        11.16          1.17      0.26              3.54 × 10^−3^    324.05874   ↓                                 Pyrimidine metabolism
  CDP-choline                          ESI(+), ESI(−)        10.48          1.42      0.19              6.84 × 10^−4^    489.11378   ↓                                 Others
  Fructose 1-phosphate                 ESI(−)                11.67          1.39      0.18              1.10 × 10^−5^    259.02169   ↓                                 Glycolysis/gluconeogenesis
  D-Glucosamine 1-phosphate            ESI(−)                9.37           1.62      0.11              9.85 × 10^−6^    258.03715   ↓                                 Others
  Azelaic acid                         ESI(−)                6.52           1.11      0.24              3.40 × 10^−3^    187.09704   ↓                                 Others
  Betaine                              ESI(+)                4.43           1.61      0.15              5.08 × 10^−9^    118.08595   ↓                                 Amino acid metabolism
  Beta-D-Fructose 2-phosphate          ESI(+)                10.96          1.22      0.28              3.37 × 10^−5^    261.03660   ↓                                 Fructose and mannose metabolism
  Allocystathionine                    ESI(+)                13.25          1.05      0.32              0.01             223.07394   ↓                                 Others
  alpha-ketoglutarate                  ESI(−)                7.42           1.66      0.09              4.02 × 10^−3^    145.01419   ↓                                 TCA cycle
  2-Oxoadipic acid                     ESI(−)                3.08           1.33      2.42              5.07 × 10^−4^    141.01637   ↑                                 Amino acid metabolism
  2-Ethyl-2-Hydroxybutyric acid        ESI(−)                1.57           2.08      0.03              6.94 × 10^−4^    131.07108   ↓                                 Others
  Acetylcarnitine                      ESI(+)                5.30           2.24      0.03              2.36 × 10^−9^    204.12232   ↓                                 Others
  7-Methylguanosine                    ESI(+)                5.82           1.29      0.08              0.10             298.11150   ↓                                 Purine metabolism
  4-Pyridoxic acid                     ESI(+)                4.26           1.67      0.13              1.49 × 10^−7^    244.07854   ↓                                 Vitamin metabolism
  4-Guanidinobutyric acid              ESI(+)                6.99           1.11      0.30              6.75 × 10^−4^    146.09158   ↓                                 Others
  3-Hydroxyanthranilic acid            ESI(+)                6.58           1.93      0.07              2.75 × 10^−6^    154.04900   ↓                                 Others
  1-Methyladenosine                    ESI(+)                4.87           1.01      0.36              5.55 × 10^−4^    282.11910   ↓                                 Purine metabolism
  (S)-2-Hydroxyglutarate               ESI(−)                8.34           1.77      0.07              1.14 × 10^−3^    147.02980   ↓                                 Others
  (S)-2-aminobutyric acid              ESI(−)                8.51           1.55      0.13              2.87 × 10^−7^    102.05681   ↓                                 Others

*Trend: Relative metabolite levels in B. cinerea mycelia treated with TTO in comparison with control (↑, upregulated; ↓, downregulated). PC, phosphatidylcholine; AMP, adenosine monophosphate; GMP, guanosine 5′-monophosphate; UMP, uridine 5′-monophosphate; UDP, uridine 5′-diphosphate; ADMA, NG, NG-dimethyl-L-arginine; CMP, cytidine 5′-monophosphate. GMP^172^ and GMP^173^ designate different molecules; their adducts are (M+H)^+^ and (M+H-H~2~O)^+^, respectively. Differences with VIP \> 1 and 0.05 \< P \< 0.1 are considered significant*.

Hierarchical clustering analysis
--------------------------------

Table [1](#T1){ref-type="table"} shows the metabolic changes in fungal cells after treatment with TTO. The metabolites identified include products and intermediates generated by the TCA cycle, fatty acids, amino acids, and carbohydrates. The results suggest that *B. cinerea* adapts to environmental changes by regulating metabolic pathways. To provide an intuitive representation of the discriminatory power of the selected biomarkers in untreated and TTO-treated *B. cinerea*, a visual hierarchical clustering analysis (HCA, Figure [2](#F2){ref-type="fig"}) was performed. Each rectangle in the heat map represents one metabolite and is colored based on a normalized scale from −2 (low) to 2 (high). Differences between control and treated groups are the result of metabolite alterations after treatment with TTO. In positive mode (Figure [2A](#F2){ref-type="fig"}), seven metabolites \[glycyl-L-leucine, L-carnosine, imidazoleacetic acid, L-methionine, N-(omega)-hydroxyarginine, guanosine, and deoxyadenosine\] were upregulated in the TTO-treated sample, accounting for 10.3% of metabolites in positive mode. Other metabolites such as L-arginine, D-glucose 6-phosphate, phosphatidylcholine, alpha-linolenic acid, D-mannitol, and L-glutamate were downregulated in the TTO-treated sample, accounting for 89.7% of metabolites in positive mode. In negative mode (Figure [2B](#F2){ref-type="fig"}), glycyl-L-leucine, 2-oxoadipic acid, and guanosine were upregulated in the TTO-treated sample, accounting for 7.3% of metabolites in negative mode, while other metabolites such as isocitrate, L-malic acid, succinate, L-alanine, and trehalose were downregulated in the TTO-treated sample, accounting for 92.7% of metabolites in negative mode.

![Heat map visualizing changes in levels of potential biomarkers in positive mode **(A)** and negative mode **(B)**. Rows: biomarkers; Columns: samples. The color key indicates the biomarker content ratio (blue: lowest; red: highest.) C, control sample; T, TTO-treated sample.](fmicb-08-01017-g0002){#F2}

Isocitrate, L-malic acid, succinate, and α-ketoglutarate are all involved in the TCA cycle. The contents of these compounds were all markedly decreased by 81.2, 84.1, 94.9, and 91.9%, respectively, in TTO-treated *B. cinerea* compared to the untreated control (Figure [2](#F2){ref-type="fig"}). Phosphatidylcholine and alpha-linolenic acid are related to the fatty acid. The levels of phosphatidylcholine and alpha-linolenic acid compared with control downregulated 68.3% and 83.3% respectively in TTO-treated cells (Figure [3](#F3){ref-type="fig"}). As illustrated in Table [1](#T1){ref-type="table"}, the detected L-carnosine and imidazoleacetic acid in TTO-treated groups compared with control was distinctly increased to 8.54- and 3.44-fold, respectively.

![General biosynthetic pathway for selected metabolites as obtained from the KEGG database. Metabolites in red denote metabolites that are relatively more abundant in the TTO-treated sample, while metabolites in blue denote metabolites that are relatively less abundant.](fmicb-08-01017-g0003){#F3}

Effects of TTO on changes of key enzymes activities involved in TCA cycle, H~2~O~2~ accumulation, and leakage of cell membrane
------------------------------------------------------------------------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, the activities of MDH, SDH, CS, ICDH and α-KGDH in untreated cells was 54.87 U/g, 23.75 U/g, 366.24 U/g, 647.50 U/g and 355.55 U/g, respectively. After treatment with TTO at 5 mL/L for 2 h, the activities for these enzymes decreased about 79.3, 78.9, 83.3, 66.0, and 91.7%, respectively. It indicated that all of these key enzymes involved in TCA cycle were significantly reduced in *B. cinerea* treated with TTO.

###### 

Effect of TTO on SDH, MDH, CS, ICDH, α-KGDH, activities and H~2~O~2~ content in *B. cinerea* cells.

  **Treatment**   **SDH (U/g)[^\*^](#TN2){ref-type="table-fn"}**   **MDH (U/g)[^\*^](#TN2){ref-type="table-fn"}**   **CS (U/g)[^\*^](#TN2){ref-type="table-fn"}**    **ICDH (U/g)[^\*^](#TN2){ref-type="table-fn"}**   **α-KGDH (U/g)[^\*^](#TN2){ref-type="table-fn"}**   **H~2~O~2~ (mmol/g prot)[^\*^](#TN2){ref-type="table-fn"}**
  --------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------
  Control         23.75 ± 2.54[^a^](#TN1){ref-type="table-fn"}     54.87 ± 1.24[^a^](#TN1){ref-type="table-fn"}     366.24 ± 25.44[^a^](#TN1){ref-type="table-fn"}   647.50 ± 18.72[^a^](#TN1){ref-type="table-fn"}    355.55 ± 17.96[^a^](#TN1){ref-type="table-fn"}      43.65 ± 6.85[^b^](#TN1){ref-type="table-fn"}
  TTO             5.00 ± 1.53[^b^](#TN1){ref-type="table-fn"}      11.35 ± 1.50[^b^](#TN1){ref-type="table-fn"}     61.16 ± 9.22[^b^](#TN1){ref-type="table-fn"}     220.29 ± 41.46[^b^](#TN1){ref-type="table-fn"}    29.46 ± 3.74[^b^](#TN1){ref-type="table-fn"}        120.95 ± 12.25[^a^](#TN1){ref-type="table-fn"}

*differences are significant at P \< 0.05 based on Duncan\'s multiple range tests*.

*Values are presented as mean ± standard deviation*.

Meanwhile, H~2~O~2~ content increased from 43.65 mmol/g prot to 120.95 mmol/g prot because of TTO treatment (Table [2](#T2){ref-type="table"}). Absorbance at 260 nm increased by 14% after TTO treatment for 2 h, while the control group increased by only 1% (Figure [4](#F4){ref-type="fig"}). It was suggested that TTO led to the accumulation of H~2~O~2~ and the leakage of cell membrane.

![Effects of TTO treatment on *B. cinerea* as measured by percentage absorbance change at 260 nm. Vertical bars represent the standard deviation of the means. a,b: significant differences at *P* \< 0.05 level.](fmicb-08-01017-g0004){#F4}

Discussion {#s4}
==========

Evidence suggests that essential oils damage fungal cell membranes, resulting in prolific leakage of ions, and nutrients. The leakage can be measured as an increase in absorbance at 260 nm and increasing conductivity in the medium (Hood et al., [@B16]; Tao et al., [@B40]). In our metabolomics analysis (Table [1](#T1){ref-type="table"}), the majority of metabolites (83) were downregulated in the TTO-treated sample, perhaps due to the disruption of the cell membrane and metabolite leakage. But some metabolites (8) were upregulated in the TTO-treated sample. Shao et al. ([@B34]) showed that TTO treatment causes membrane leakage in *B. cinerea*, an increase in the activity of alkaline phosphatase, and an increase in palmitic acid (C16:0), stearic acid (C18:0), and oleic acid (C18:1) content was observed. Therefore, even after membrane integrity is compromised, some compounds may accumulate, possibly in response to stress.

The TCA cycle is the metabolic process by which ATP is generated in mitochondria, and is widely conserved in all oxidative organisms (Regev-Rudzki, [@B31]; Mailloux et al., [@B25]). The pathway contains several key enzymes (SDH, MDH, CS, ICDH, α-KGDH) and produces critical intermediates such as isocitrate, succinate, malate, and alpha-ketoglutarate (Li et al., [@B18]; Guo et al., [@B12]). As shown in Figure [2](#F2){ref-type="fig"}, TTO caused decreases in the levels of isocitrate, L-malic acid, succinate, and α-ketoglutarate. Mousavi et al. demonstrated that the levels of metabolites related to the TCA cycle, such as malic acid and glucose 6-phosphate, decreased in *E. coli* after treatment with cinnamaldehyde, suggesting downregulation of the TCA cycle (Mousavi et al., [@B26]). It is therefore possible that the TCA cycle of *B. cinerea* is also inhibited by TTO treatment.

To test our hypothesis, we measured the activities of MDH, SDH, CS, ICDH, and α-KGDH, key enzymes associated with the TCA cycle. As shown in Table [2](#T2){ref-type="table"}, treatment with TTO at 5 mL/L for 2 h markedly decreased activities for these enzymes. In *Penicillium digitatum* cells, citral treatment inhibits the TCA pathway, as demonstrated by the reduction in citric acid content and reduction in the activities of CS, SDH, ICDH, and α-KGDH, although MDH activity increases (Zheng et al., [@B45]). However, MDH and SDH activities in *Sclerotinia sclerotiorum* and *Rhizopus nigricans* cells are decreased by dill seed essential oil and cinnamon oil, respectively (Li et al., [@B20]; Wang et al., [@B43]). Essential oils cause mitochondrial dysfunction by decreasing the activities of TCA-related enzymes, causing the accumulation of reactive oxygen species (ROS) and ultimately resulting in cell apoptosis (Tian et al., [@B41]; Zheng et al., [@B45]). Li et al. ([@B21]) revealed that TTO severely damaged mitochondria of *B. cinerea*, resulting in matrix loss and increased mitochondrial irregularity. H~2~O~2~, an important ROS, can cause membrane lipid peroxidation and generation of protein carbonyl groups (Singh et al., [@B37]; Wang et al., [@B42]). TTO treatment increased H~2~O~2~ (Table [2](#T2){ref-type="table"}), potentially resulting in oxidative stress and changes in the composition of cell membrane fatty acids. Together, these results suggest that TTO inhibits TCA cycle, possibly causing mitochondrial dysfunction and oxidation stress in *B. cinerea*.

Phosphatidylcholine is the major polar lipid in *B. cinerea*, while alpha-linolenate is the primary fatty acid (Griffiths et al., [@B11]). Both are major components of the cell membrane. Dill oil, which targets the plasma membrane of *A. flavus*, disrupts ergosterol biosynthesis (Khan et al., [@B17]; Tian et al., [@B41]). Citral exposure affects the expression of some genes involved in cell membrane-related pathways such as fatty acid biosynthesis and fatty acid metabolism, suggesting that it destroys cell membrane integrity (Ouyang et al., [@B27]). Citral, octanal, and α-terpineol decrease the total lipid content in *Geotrichum citri-aurantii* cells, causing the destruction of the cell membrane (Zhou et al., [@B46]). We previously reported that TTO treatment decreases the unsaturated/saturated fatty acid ratio in *B. cinerea*, suggesting that cell membrane disruption is related to changes in fatty acid composition (Shao et al., [@B34]). In this study, phosphatidylcholine and alpha-linolenic acid were downregulated in TTO-treated cells (Figure [3](#F3){ref-type="fig"}), as well as the leakage of cell membrane (Figure [4](#F4){ref-type="fig"}). These results imply that TTO promotes membrane leakage either directly, or indirectly by interfering with membrane lipid biosynthesis and fatty acid composition.

A dramatic increase in H~2~O~2~ content was detected in *B. cinerea* cells incubated with TTO (Table [2](#T2){ref-type="table"}), which demonstrates that TTO treatment increases the level of free radicals, resulting in oxidative stress. L-carnosine (beta-alanyl-L-histidine) is a natural dipeptide with antioxidant activity and functions as a scavenger for free-radicals (Hipkiss, [@B15]; Boldyrev et al., [@B6]). L-carnosine levels increased in the TTO-treated sample, perhaps as a protective response against H~2~O~2~-induced oxidative stress. L-carnosine has a similar function in red blood cells subjected to oxidative stress by H~2~O~2~ (Aydogan et al., [@B3]).

The binding of γ-aminobutyric acid (GABA) to the GABA receptor triggers changes in plasma membrane ionic permeability (Perfilova and Tiurenkov, [@B29]). At least three types of GABA receptors, designated GABA~*A*~, GABA~*B*~, and GABA~*C*~, have been characterized (Qian and Dowling, [@B30]). Imidazoleacetic acid is a major catabolite of histamine and functions as a GABA~*C*~ receptor antagonist (Liu et al., [@B23]). Our data show that TTO treatment increases membrane permeability in *B. cinerea* (Figure [4](#F4){ref-type="fig"}) and also increases the level of imidazoleacetic acid in *B. cinerea* (Figure [3](#F3){ref-type="fig"}). The increase in the level of imidazoleacetic acid may inhibit binding to the GABA~C~ receptor, conferring partial protection against membrane leakage induced by TTO-treatment.

Conclusion {#s5}
==========

This report presents the first metabolomics analysis of *B. cinerea* after treatment by TTO, and demonstrates that TTO disrupts the TCA cycle, affects the level of various cellular components, and causes cell membrane leakage. The damage results in mitochondrial dysfunction and oxidative stress. L-carnosine and imidazoleacetic acid levels increase in response to these events.
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